Kit
Case
FSA/HSA Eligible
FSA/HSA Eligible
The BD Veritor System for Rapid Detection of SARS-CoV-2 is a chromatographic digital immunoassay designed for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal swab specimens. This test is intended for use by healthcare providers in individuals suspected of COVID-19, both symptomatic (within the first 5 days of symptom onset) and asymptomatic, when tested in a specific sequence over several days. It is authorized for use at the Point of Care (POC) in settings with CLIA certification, whether for waived, moderate, or high complexity testing.
This system does not differentiate between SARS-CoV and SARS-CoV-2 but is intended to identify SARS-CoV-2 nucleocapsid protein antigen, generally detectable during the acute phase of infection. Positive results indicate the presence of viral antigens but should be interpreted alongside clinical history and other diagnostic information to assess the patient's infection status. They do not rule out bacterial infections or co-infections with other viruses, and the detected agent may not be the definitive cause of disease. All results must be reported to the appropriate public health authorities.
Negative results are considered presumptive, and if necessary for patient management, confirmation with a molecular assay may be performed. Negative results should not be the sole basis for treatment or patient management decisions, including infection control measures. These results should be evaluated in the context of the individual's recent exposures, history, and clinical symptoms consistent with COVID-19.
The BD Veritor System employs a dedicated opto-electronic interpretation instrument and immunochromatographic assays. It is designed to detect SARS-CoV-2 nucleocapsid proteins in respiratory samples from patients with signs and symptoms of infection or those undergoing serial testing. When specimens are processed, the SARS-CoV-2 antigens bind to antibodies conjugated to detector particles on the test strip. The antigen-conjugate complexes migrate to the reaction area and are captured by antibodies on the membrane. The BD Veritor Plus Analyzer determines a positive result when the antigen-conjugate is deposited at both the Test "T" and Control "C" positions on the device, analyzing and correcting for non-specific binding to provide an objective result.
Features:
Kit Includes:
Warnings and Precautions:
Storage:
Kits may be stored at 2–30 °C. DO NOT FREEZE. Reagents and devices must be at room temperature (15–30 °C) when used for testing.
Brand | BD Veritor System |
Application | Respiratory Test Kit |
CLIA Classified | CLIA Waived |
Contents 1 | (30) Single-use Test Devices, (30) Single-use Reaction Tubes, (30) Sterile Single-use Specimen Sampling Swabs, Positive SARS-CoV-2 Control Swab, Negative SARS-CoV-2 Control Swab, Instructions for Use, Quick Reference Card, Nasal Sampling Instructions |
For Use With | For use with the BD Veritor Plus Analyzer running Firmware version 5.4 or later |
Number of Tests | 30 Tests |
Purchase Program Type | Standard Purchase |
Reading Type | Machine Read |
Sample Type | Nasal Swab Sample |
Specialty | Immunoassay |
Test Format | Test Device Format |
Test Method | Chromatographic Digital Immunoassay |
Test Name | SARS-CoV-2 |
Test Type | Infectious Disease Immunoassay |
Time to Results | 15 Minute Results |
Please call us for specific details.
Please call us for specific details.
The BD Veritor System for Rapid Detection of SARS-CoV-2 is a chromatographic digital immunoassay designed for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal swab specimens. This test is intended for use by healthcare providers in individuals suspected of COVID-19, both symptomatic (within the first 5 days of symptom onset) and asymptomatic, when tested in a specific sequence over several days. It is authorized for use at the Point of Care (POC) in settings with CLIA certification, whether for waived, moderate, or high complexity testing.
This system does not differentiate between SARS-CoV and SARS-CoV-2 but is intended to identify SARS-CoV-2 nucleocapsid protein antigen, generally detectable during the acute phase of infection. Positive results indicate the presence of viral antigens but should be interpreted alongside clinical history and other diagnostic information to assess the patient's infection status. They do not rule out bacterial infections or co-infections with other viruses, and the detected agent may not be the definitive cause of disease. All results must be reported to the appropriate public health authorities.
Negative results are considered presumptive, and if necessary for patient management, confirmation with a molecular assay may be performed. Negative results should not be the sole basis for treatment or patient management decisions, including infection control measures. These results should be evaluated in the context of the individual's recent exposures, history, and clinical symptoms consistent with COVID-19.
The BD Veritor System employs a dedicated opto-electronic interpretation instrument and immunochromatographic assays. It is designed to detect SARS-CoV-2 nucleocapsid proteins in respiratory samples from patients with signs and symptoms of infection or those undergoing serial testing. When specimens are processed, the SARS-CoV-2 antigens bind to antibodies conjugated to detector particles on the test strip. The antigen-conjugate complexes migrate to the reaction area and are captured by antibodies on the membrane. The BD Veritor Plus Analyzer determines a positive result when the antigen-conjugate is deposited at both the Test "T" and Control "C" positions on the device, analyzing and correcting for non-specific binding to provide an objective result.
Features:
Kit Includes:
Warnings and Precautions:
Storage:
Kits may be stored at 2–30 °C. DO NOT FREEZE. Reagents and devices must be at room temperature (15–30 °C) when used for testing.
Brand | BD Veritor System |
Application | Respiratory Test Kit |
CLIA Classified | CLIA Waived |
Contents 1 | (30) Single-use Test Devices, (30) Single-use Reaction Tubes, (30) Sterile Single-use Specimen Sampling Swabs, Positive SARS-CoV-2 Control Swab, Negative SARS-CoV-2 Control Swab, Instructions for Use, Quick Reference Card, Nasal Sampling Instructions |
For Use With | For use with the BD Veritor Plus Analyzer running Firmware version 5.4 or later |
Number of Tests | 30 Tests |
Purchase Program Type | Standard Purchase |
Reading Type | Machine Read |
Sample Type | Nasal Swab Sample |
Specialty | Immunoassay |
Test Format | Test Device Format |
Test Method | Chromatographic Digital Immunoassay |
Test Name | SARS-CoV-2 |
Test Type | Infectious Disease Immunoassay |
Time to Results | 15 Minute Results |
Please call us for specific details.
Please call us for specific details.
Kit
Case